智通财经获悉，今日(12月19日)，中国国家药监局药品审评中心(CDE)官网公示，第一三共(DSNKY.US)申报的1类新药DS-3939a临床试验申请已获得受理。公开资料显示，DS-3939a是一种靶向TA-MUC1的抗体偶联药物(ADC)，正在全球范围内处于1/2期临床研究阶段。根据CDE官网查询，本次为该产品首次在中国申报临床。MUC1是...
研究表明,TA-MUC1在多种实体瘤中高表达,包括尿路上皮癌、非小细胞肺癌、乳腺癌、卵巢癌、胆道癌和胰腺癌等。因此,TA-MUC1成为了一个极具潜力的肿瘤治疗靶点。DS-3939a正是基于这一靶点设计的ADC药物,旨在通过特异性地靶向TA-MUC1,实现对肿...
DS-3939 is a specifically engineered potential first-in-class tumor-associated mucin-1 (TA-MUC1) directed antibody drug conjugate (ADC) designed using Daiichi Sankyo’s proprietary DXd ADC technology. TA-MUC1 is a tumor-specific transmembrane glycoprotein and is overexpressed...
The anti-TA-MUC1 is the antibody contained in DS-3939, an ADC being developed byDaiichi Sankyo. DS-3939 is a specifically engineered potential first-in-class TA-MUC1 directed medicine designed using Daiichi Sankyo’s proprietary DXd ADC technology. DS-3939 is currently being evaluated in ...
DS-3939a also induced strong tumor regression even after treatment of other cytotoxic ADCs in several xenograft models.Conclusion: Based on these preclinical results, DS-3939a could provide valuable therapy with potential benefits for patients with TA-MUC1-expressing tumors. A first-in-human phase ...
当DS-8201在中国获批半年即创下7.3亿销售额时,第一三共DS-3939a的临床批件再次将目光引向肿瘤治疗靶点创新的深水区。数据显示,目前全球在研ADC项目中83%集中在HER2、TROP2等成熟靶点,而MUC1这一新靶点的突破,或将重构实体瘤治疗的竞争格局。 作为跨膜蛋白家族的特殊成员,MUC1在正常细胞中承担着细胞保护与信号...
DS-3939a is a novel antibody-drug conjugate in development for the treatment of malignant tumors composed of a humanized anti-TA-MUC1 antibody, a peptide-based cleavable linker, and a potent topoisomerase I inhibitor (deruxtecan [DXd]). This study will assess the safety, tolerability, and ...
DS-3939a is a novel antibody-drug conjugate in development for the treatment of malignant tumors composed of a humanized anti-TA-MUC1 antibody, a peptide-based cleavable linker, and a potent topoisomerase I inhibitor (DXd). This study will assess the safety, tolerability, and efficacy of DS-...
智通财经APP获悉,今日(12月19日),中国国家药监局药品审评中心(CDE)官网公示,第一三共(DSNKY.US)申报的1类新药DS-3939a临床试验申请已获得受理。公开资料显示,DS-3939a是一种靶向TA-MUC1的抗体偶联药物(ADC),正在全球范围内处于1/2期临床研究阶段。根据CDE官网查询,本次为该产品首次在中国申报临床。
智通财经APP获悉,今日(12月19日),中国国家药监局药品审评中心(CDE)官网公示,第一三共(DSNKY.US)申报的1类新药DS-3939a临床试验申请已获得受理。公开资料显示,DS-3939a是一种靶向TA-MUC1的抗体偶联药物(ADC),正在全球范围内处于1/2期临床研究阶段。根据CDE官网查询,本次为该产品首次在中国申报临床。